{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T11:47:09Z","timestamp":1782560829793,"version":"3.54.5"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone Reports"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.bonr.2026.101904","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T08:05:31Z","timestamp":1770365131000},"page":"101904","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Successful management of denosumab discontinuation in a patient with primary pediatric osteoporosis"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9624-6296","authenticated-orcid":false,"given":"Athanasios D.","family":"Anastasilakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polyzois","family":"Makras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stergios A.","family":"Polyzos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria P.","family":"Yavropoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Socrates E.","family":"Papapoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bonr.2026.101904_bb0005","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1007\/s00198-021-06002-5","article-title":"Denosumab for the treatment of primary pediatric osteoporosis","volume":"32","author":"Anastasilakis","year":"2021","journal-title":"Osteoporos.Int."},{"key":"10.1016\/j.bonr.2026.101904_bb0010","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/jbmr.3110","article-title":"Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases","volume":"32","author":"Anastasilakis","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bonr.2026.101904_bb0015","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1007\/s00223-024-01202-7","article-title":"Medical management for fracture prevention in children with osteogenesis imperfecta","volume":"115","author":"Arundel","year":"2024","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bonr.2026.101904_bb0020","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.bonr.2026.101904_bb0025","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1080\/14740338.2024.2379446","article-title":"Hypercalcemia in children induced by denosumab: a case report and an analysis of the FDA adverse event reporting system database","volume":"24","author":"Chen","year":"2025","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.bonr.2026.101904_bb0030","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1056\/NEJMc2214862","article-title":"Safety and Efficacy of Denosumab for Fibrous Dysplasia of Bone","volume":"388","author":"de Castro","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bonr.2026.101904_bb0035","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41584-023-00935-3","article-title":"Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone","volume":"19","author":"Ferrari","year":"2023","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.bonr.2026.101904_bb0040","article-title":"Hypercalcemia following discontinuation of denosumab therapy: A systematic review","volume":"15","author":"Horiuchi","year":"2021","journal-title":"Bone Rep."},{"key":"10.1016\/j.bonr.2026.101904_bb0045","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1210\/clinem\/dgad732","article-title":"Safety and Efficacy of Denosumab in Children With Osteogenesis Imperfecta-the First Prospective Comparative Study","volume":"109","author":"Liu","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bonr.2026.101904_bb0050","doi-asserted-by":"crossref","first-page":"e4155","DOI":"10.1210\/clinem\/dgab321","article-title":"The Duration of Denosumab Treatment and the Efficacy of Zoledronate to Preserve Bone Mineral Density After Its Discontinuation","volume":"106","author":"Makras","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bonr.2026.101904_bb0055","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s00198-025-07538-6","article-title":"No overshoot of bone turnover after withdrawal of denosumab treatment of adults with Langerhans cell histiocytosis: a prospective clinical trial","volume":"36","author":"Makras","year":"2025","journal-title":"Osteoporos.Int."},{"key":"10.1016\/j.bonr.2026.101904_bb0060","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1002\/jbmr.4380","article-title":"Safety of therapy with and withdrawal from denosumab in fibrous dysplasia and McCune-Albright syndrome: an observational study","volume":"36","author":"Meier","year":"2021","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bonr.2026.101904_bb0070","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00223-023-01065-4","article-title":"Mitigating the Denosumab-Induced Rebound Phenomenon with Alternating Short- and Long-Acting Anti-resorptive Therapy in a Young Boy with Severe OI Type VI","volume":"112","author":"Seale","year":"2023","journal-title":"Calcif. Tissue Int."},{"issue":"10","key":"10.1016\/j.bonr.2026.101904_bb0075","doi-asserted-by":"crossref","first-page":"ziaf140","DOI":"10.1093\/jbmrpl\/ziaf140","article-title":"Urinary calcium and bone resorption markers during 3 years of denosumab treatment in pediatric osteogenesis imperfecta","volume":"9","author":"Stasek","year":"2025","journal-title":"JBMR Plus"},{"key":"10.1016\/j.bonr.2026.101904_bb0080","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1007\/s12519-020-00378-w","article-title":"Hypercalcaemia after treatment with denosumab in children: bisphosphonates as an option for therapy and prevention?","volume":"16","author":"Sydlik","year":"2020","journal-title":"World J. Pediatr."},{"key":"10.1016\/j.bonr.2026.101904_bb0085","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","author":"Tsourdi","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bonr.2026.101904_bb0090","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1210\/clinem\/dgad657","article-title":"Management of RANKL-mediated Disorders With Denosumab in Children and Adolescents: A Global Expert Guidance Document","volume":"109","author":"Vanderniet","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Bone Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352187226000082?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352187226000082?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T11:29:42Z","timestamp":1782559782000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352187226000082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":17,"alternative-id":["S2352187226000082"],"URL":"https:\/\/doi.org\/10.1016\/j.bonr.2026.101904","relation":{},"ISSN":["2352-1872"],"issn-type":[{"value":"2352-1872","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Successful management of denosumab discontinuation in a patient with primary pediatric osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Bone Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bonr.2026.101904","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101904"}}